{
    "nct_id": "NCT00750529",
    "title": "Effects of Galantamine and Don\u00e9p\u00e9zil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.",
    "status": "COMPLETED",
    "last_update_time": "2014-07-04",
    "description_brief": "The aim of the study is the analysis of two inhibitors of Ach-E: galantamine and don\u00e9p\u00e9zil in over 65 years' old patients suffering from Alzheimer disease (MMSE between 20 and 26) without Alzheimer's medication.",
    "description_detailed": "Feasibility study, open, randomized, controlled, cross-over study in 65 years old patients.",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "galantamine (acetylcholinesterase inhibitor)",
        "donepezil (acetylcholinesterase inhibitor)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests two acetylcholinesterase (AChE) inhibitors \u2014 galantamine and donepezil \u2014 in patients with mild Alzheimer disease to assess effects on sleep; these drugs are approved to improve cognition/symptoms in AD rather than to remove or target core pathology (amyloid/tau). \ue200cite\ue202turn0search2\ue202turn0search4\ue201",
        "Act: Extracted details from the description \u2014 interventions are galantamine and donepezil (both AChE inhibitors). The title/aim focus on sleep effects, but the agents' primary indication is symptomatic cognitive enhancement in AD; the trial does not describe a disease-modifying biologic or a psychiatric-specific intervention. \ue200cite\ue202turn0search8\ue202turn0search7\ue201",
        "Reflect: Classification \u2014 these drugs fit the 'Cognitive enhancer' category because they enhance cholinergic neurotransmission to improve cognitive and related clinical symptoms in AD, and guidance/reviews note they provide symptomatic benefit without evidence of changing disease course. Therefore the correct category is 'cognitive enhancer'. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Web search results (key sources used): 1) Galantamine \u2014 review describing galantamine as a reversible AChE inhibitor with nicotinic receptor potentiation and symptomatic cognitive benefits in mild\u2013moderate AD. \ue200cite\ue202turn0search2\ue202turn0search8\ue201 2) Donepezil \u2014 reviews/entries describing donepezil as a centrally acting, reversible AChE inhibitor approved for symptomatic treatment of mild to severe AD; not disease-modifying. \ue200cite\ue202turn0search4\ue202turn0search3\ue201 3) Systematic/cochrane-style evidence summarizing that galantamine improves cognitive function and function vs placebo at typical doses (symptomatic effects). \ue200cite\ue202turn0search5\ue201 4) Additional pharmacology/review articles on donepezil supporting symptomatic benefit and mechanism. \ue200cite\ue202turn0search1\ue202turn0search10\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests two acetylcholinesterase inhibitors (galantamine and donepezil) that increase synaptic acetylcholine and modulate cholinergic/nicotinic signalling to produce symptomatic cognitive and related effects in AD. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Act: Extracted details \u2014 interventions are galantamine (a reversible AChE inhibitor that also allosterically potentiates nicotinic receptors) and donepezil (a centrally acting, reversible AChE inhibitor). These mechanisms act on cholinergic neurotransmission rather than directly on amyloid, tau, inflammation, or other core disease-modifying pathways, so the CADRO category matching neurotransmitter systems is most specific. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Confirmation \u2014 classification as 'D) Neurotransmitter Receptors' fits the drugs' mechanism (cholinesterase inhibition and nicotinic modulation) and the trial\u2019s symptomatic/cognitive-enhancer intent (sleep effects are an outcome measure, but the agents\u2019 pharmacology is cholinergic). No evidence in the description that the trial targets amyloid, tau, ApoE/lipids, inflammation, or is multi-target disease modification, so D is appropriate. \ue200cite\ue202turn0search4\ue202turn0search6\ue201",
        "Web search results used (key sources): 1) Galantamine review describing reversible acetylcholinesterase inhibition and nicotinic receptor modulation. \ue200cite\ue202turn0search2\ue202turn0search0\ue201 2) Donepezil review describing central, reversible acetylcholinesterase inhibition and symptomatic benefit in AD. \ue200cite\ue202turn0search3\ue201 3) Additional clinical/pharmacology reviews of galantamine and donepezil noting symptomatic (not disease-modifying) effects. \ue200cite\ue202turn0search4\ue202turn0search6\ue201"
    ]
}